Gracell Biotechnologies Inc. announced the appointment Of Wendy Li, M.D., as its Chief Medical Officer. In this role, Dr. Li will oversee Gracell's clinical development activities, including the advancement of its pipeline of autologous and allogeneic product candidates across the Company's multiple proprietary technology platforms. Dr. Li brings to Gracell over 20 years of experience leading all critical aspects of clinical and medical operations at early-stage and large pharmaceutical organizations in the U.S. and China. Her expertise spans both clinical development and medical affairs, including leading early- and late-stage clinical trials for several therapeutic candidates for the treatment of hematological malignancies and solid tumors, and overseeing over 30 successful Investigational New Drug applications, New Drug Applications and Biologics License Applications that led to several multi-billion-dollar blockbuster drugs.

Prior to joining Gracell, Dr. Li served as CMO of EXUMA Biotech, where she provided strategic medical and clinical leadership for the advancement of its cell therapy pipeline in the U.S. and Asia. She has also held clinical development and medical affairs leadership positions at Pfizer, Sanofi, Genentech, and Sihuan Pharmaceutical. Dr. Li holds an M.D. from Sun Yat-Sen University of Medical Sciences.